Работы, на которые ссылается эта работа

Работ: 171

Работа: Exploring cellular immunotherapy platforms in multiple myeloma

Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9
Обзорная статья2018Цитирований: 11
ABI
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao +3
Обзорная статья2023Цитирований: 6
ABI
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25
Статья2021Цитирований: 5
ABI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin +20
Статья2019Цитирований: 4
ABI
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
Статья2022Цитирований: 4
ABI
Bispecific T‐cell engagers for cancer immunotherapy
Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman
Обзорная статья2014Цитирований: 3
ABI
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12
Статья2021Цитирований: 3
ABI
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianjun Chu, Youcai Deng, D.M. Benson +13
Статья2013Цитирований: 3
ABI
<i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8
Статья2007Цитирований: 3
ABI
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert +4
Обзорная статья2015Цитирований: 3
ABI
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Joseph D. Malaer, Porunelloor A. Mathew
Статья2017Цитирований: 3
ABI
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21
Статья2018Цитирований: 3
ABI
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Na Tang, Chen Cheng, Xingying Zhang +6
Статья2020Цитирований: 3
ABI
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang +3
Обзорная статья2020Цитирований: 3
ABI
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman, Joshua Richter, Ajai Chari
Обзорная статья2020Цитирований: 3
ABI
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2
Обзорная статья2021Цитирований: 3
ABI
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Ben Creelan, Chao Wang, Jamie K. Teer +23
Статья2021Цитирований: 3
ABI
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han +2
Обзорная статья2022Цитирований: 3
ABI
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
Feifei Li, Sheng Liu
Обзорная статья2022Цитирований: 3
ABI
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5
Статья2016Цитирований: 2
ABI
CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?
María C. Ramello, Eric B. Haura, Daniel Abate‐Daga
Статья2017Цитирований: 2
ABI
The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells
Jake Moscarelli, David J. Zahavi, Rachael Maynard +1
Обзорная статья2022Цитирований: 2
ABI
Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma
Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +6
Статья2023Цитирований: 2
ABI
Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy
Min Yang, Yu Chen, Li Zhu +5
Обзорная статья2024Цитирований: 2
ABI
Ex vivo pulsed dendritic cell vaccination against cancer
Yangzhuo Gu, Xing Zhao, Xiangrong Song
Обзорная статья2020Цитирований: 2
ABI